The results confirm that cells harboring HCC-derived EGFR mutants are erlotinib-resistant, as treatment up to high concentration of erlotinib could only induce partial inhibition of EGFR phosphorylation, and partial or no inhibition of AKT and ERK phosphorylation. This evidence concerns the gene AKT1 and hepatocellular carcinoma.